Inverness v. Acon
This article was originally published in The Gray Sheet
Boston federal court grants preliminary sales injunction against Acon Laboratories' "sandwich-type immunoassay tests," including strep, pregnancy and ovulation tests, Inverness reports July 19. Inverness anticipates a sales increase as the firm obtains accounts with former Acon customers, but also expects to fall short of Q2 guidance due to higher legal expenses and "shifts in revenue mix." The suit related to Inverness' '982 patent, which the court found to be infringed. A trial slated for early November will assess Acon's patent validity challenge...
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.